Abstract: Disclosed are compounds represented by general formula (I) or pharmacologically acceptable salts or solvates thereof having excellent antimicrobial activity against bacteria causative of severe infections such as pneumonia and septicemia, particularly against MRSA, and also antimicrobial agents comprising these compounds, and pharmaceutical compositions comprising these compounds as an active component.

Abstract: A triterpene derivative useful for the treatment of hepatic disorders is disclosed. This compound comprises as an active ingredient a triterpene derivative represented by the following formula (I) or a salt thereof: wherein R1 represents a hydroxyl group, arylmethyloxy, lower alkoxy, or lower alkanoyloxy, R2 represents lower alkyl, lower alkenyl, —CH2OR5, formyl, —COOR6, or —CH2N(R7)R8, or R1 and R2 may combine with each other to form —O—C(R9)R10—O—CH2—, R3 and R4, which may be the same or different, represent a hydrogen atom, a hydroxyl group, lower alkyl, lower alkenyl, aryl, hydroxymethyl, —N(R11)R12, formyl, —COOR6, or —OR13, or R3 and R4 may combine with each other to form oxo, hydroxyimino, or alkylidene and X represents O, CH2, or NH.

Abstract: A triterpene derivative useful for the treatment of hepatic disorders is disclosed.

Abstract: A triterpene derivative useful for the treatment of hepatic disorders is disclosed. This compound comprises as an active ingredient a triterpene derivative represented by the following formula (I) or a salt thereof: wherein R1 represents a hydroxyl group, arylmethyloxy, lower alkoxy, or lower alkanoyloxy, R2 represents lower alkyl, lower alkenyl, —CH2OR5, formyl, —COOR6, or —CH2N(R7)R8, or R1 and R2 may combine with each other to form —O—C(R9)R10—O—CH2—, R3 and R4, which may be the same or different represent a hydrogen atom, a hydroxyl group, lower alkyl, lower alkenyl, aryl, hydroxymethyl, —N(R11)R12, formyl, —COOR6, or —OR13, or R3 and R4 may combine with each other to form oxo, hydroxyimino, or alkylidene and X represents O, CH2, or NH.

Abstract: A triterpene derivative useful for the treatment of hepatic disorders is disclosed.

Abstract: A pharmaceutical composition for treating a hepatic disorder, comprising a triterpene derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof is disclosed: wherein R1 represents a hydroxyl group, alkoxy, alkylcarbonyloxy, or aralkyloxy; R2 represents alkyl, —CH2OR5, wherein R5 represents a hydrogen atom, alkyl, aralkyl, or alkylcarbonyl, formyl, —COOR6, wherein R6 represents a hydrogen atom or alkyl, or —CH2N(R7)R8; or R1 and R2 combine with each other to form —O—CR9(R10)—OCH2—, wherein R9 and R10, which may be the same or different, represent a hydrogen atom, alkyl, or aryl; R3 and R4, which may be the same or different, represent a hydrogen atom, a hydroxyl group, alkyl, hydroxyalkyl, formyl, —COOR11, wherein R11 represents a hydrogen atom or alkyl, or —OR12, wherein R12 represents alkyl, aralkyl, C1-6 alkylcarbonyl, arylcarbonyl, alkenyl, alkenylcarbonyl, or arylalkenylcarbonyl which may be optionally s

Abstract: A triterpene derivative useful for the treatment of hepatic disorders is disclosed. This compound comprises as an active ingredient a triterpene derivative represented by the following formula (IV) or a salt thereof: Y represents a single bond to form a double bond in the ring with Y bonded thereto.

Abstract: 2,3-disubstituted-4-hydroxyquinoline derivatives of the general formula (I): ##STR1## [wherein R.sup.1 represents a hydrogen atom or R.sup.3 CO-- (wherein R.sup.3 is a lower alkyl group); R.sup.2 represents a hydrogen atom, --CH.sub.3 or --C.sub.2 H.sub.5 ; A represents ##STR2## and W represents a hydrogen atom, or 1- 4 halogen atoms or alkyl groups which are substituted at the nucleus and may be the same or different] have a strong antagonistic action on leukotriene D.sub.4.

Abstract: A 4-acyloxyquinoline derivative represented by the general formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.18 alkyl, C.sub.2 -C.sub.18 alkenyl, C.sub.3 -C.sub.10 cycloalkyl which may be optionally substituted, phenylloweralkyl, phenoxyloweralkyl, aryl group, a group OR.sup.4, where R.sup.4 represents a lower alkyl or aryl group, or a group ##STR2## where X represents an oxygen or a sulphur atom; R.sup.2 represents a hydrogen atom, a lower alkyl alkyl group or a group --COOR.sup.5 where R.sup.5 represents a hydrogen atom or a lower alkyl group; R.sup.3 represents a hydrogen atom, a C.sub.1 -C.sub.10 alkyl or C.sub.2 -C.sub.10 alkenyl group, provided that R.sup.1 does not represent OR.sup.4 when R.sup.2 is a hydrogen atom and R.sup.3 is methyl; R.sup.2 and R.sup.3 together represent a group (CH.sub.2).sub.

Abstract: Disclosed is a novel process for preparing [(3-amino-3-carboxy)-propyl-1]phosphinic acid derivatives, comprising reacting an alkylalkylphosphonyl halide with a vinylmagnesium halide to form a vinylphosphinic acid derivative, and reacting the vinylphosphinic acid derivative with a Shiff's base to form the aimed product. Also disclosed is a novel intermediate compound formed during the course of the above process, which compound has the general formula: ##STR1## (wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification).

Abstract: Disclosed is a novel process for optically active [(3-amino-3-carboxy)propyl-1]phosphinic acid derivatives, which comprises reacting a Shiff's base with a derivative of vinylphosphinate in the presence of a base, and subjecting the resulting compound to hydrolysis to form the optically active [(3-amino-3-carboxy)propyl-1]phosphinic acid derivatives as either [L-(3-amino-3-carboxy)propyl-1]phosphinic acid derivatives or [D-(3-amino-3-carboxy)propyl-1]phosphinic acid derivatives.